|
4 Companies |
|
1 Product |
|
1 Product |
|
3 Mechanisms of Action |
|
0 Trials |
|
10 News |
|
- | Trial completion: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=120, Completed, Sponsor: Cyprus University of Technology
Recruiting --> Completed
- | Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Recruiting --> Completed Trial primary completion date: Sep 2017 --> Aug 2018
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Trial primary completion date: Sep 2017 --> Aug 2018 Trial primary completion date: Dec 2016 --> Sep 2017
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Trial primary completion date: Dec 2016 --> Sep 2017 Trial primary completion date: May 2016 --> Dec 2016
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Oct 2015 --> May 2016
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Trial primary completion date: Oct 2015 --> May 2016 Trial primary completion date: May 2015 --> Oct 2015
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Trial primary completion date: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=30, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: May 2015 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014
- Enrollment open, Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014 Not yet recruiting --> Recruiting | Trial primary completion date: May 2014 --> May 2015
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Oct 17, 2013
P1/2, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: May 2014 --> May 2015 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1/2 trial: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Apr 23, 2012
P1/2, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital